<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690118</url>
  </required_header>
  <id_info>
    <org_study_id>GERP ALS</org_study_id>
    <secondary_id>EUDRACT NUMBER 2006-005410-13</secondary_id>
    <nct_id>NCT00690118</nct_id>
  </id_info>
  <brief_title>Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      Efficacy of pioglitazone (45 mg/day) as add-on therapy to standard therapy with riluzole in&#xD;
      patients with ALS compared to placebo in terms of survival (mortality defined exclusively as&#xD;
      death).&#xD;
&#xD;
      This is a prospective, multicentre, randomised, stratified, parallel-group, double-blind&#xD;
      trial comparing placebo with 45 mg pioglitazone as add-on therapy to 100 mg riluzole in ALS&#xD;
      in 220 enrolled patients. For entry, the El Escorial Criteria for diagnosis will be used. The&#xD;
      duration of treatment will be 18 months. The primary endpoint will be subjected to a&#xD;
      confirmatory analyses. Secondary variables will be incidence of tracheotomy or non-invasive&#xD;
      ventilation, ALS Functional Rating Scale, Quality of life and safety variables.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The interim analysis showed no tendency in favour of the verum group. Therefore it was decided&#xD;
    to stop the study prematurely.&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in patients with ALS treated with pioglitazone compared to placebo</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of tracheotomy or non-invasive ventilation</measure>
    <time_frame>18 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>45 mg/day, 18 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once daily, 18 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  possible, probable (clinically or laboratory) or definite ALS according to the revised&#xD;
             version of the El Escorial World Federation of Neurology criteria&#xD;
&#xD;
          -  disease duration more than 6 months and less than 3 years&#xD;
&#xD;
          -  best-sitting FVC between 50% and 95% of predicted normal&#xD;
&#xD;
          -  continuously treated with 100 mg riluzole daily, for at least one month&#xD;
&#xD;
          -  onset of progression weakness within 36 months prior to study&#xD;
&#xD;
          -  women of childbearing age be non-lactating and surgically sterile or using a highly&#xD;
             effective method of birth control and have a negative pregnancy test&#xD;
&#xD;
          -  capable of thoroughly understanding all information given and giving full informed&#xD;
             consent according to GCP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous participation in another clinical study within the preceding three months&#xD;
&#xD;
          -  tracheotomy or assisted ventilation of any type during the preceding three months&#xD;
&#xD;
          -  gastrostomy&#xD;
&#xD;
          -  any medical condition known to have an association with motor neuron dysfunction which&#xD;
             might confound or obscure the diagnosis of ALS&#xD;
&#xD;
          -  presence of any concomitant life-threatening disease or impairment likely to interfere&#xD;
             with functional assessment&#xD;
&#xD;
          -  confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT more than&#xD;
             1.5 upper limit of normal)&#xD;
&#xD;
          -  renal insufficiency (serum creatinine more than 2.26 mg/dl)&#xD;
&#xD;
          -  evidence of major psychiatric disorder or clinically evident dementia precluding&#xD;
             evaluation of symptoms&#xD;
&#xD;
          -  known hypersensitivity to any component of the study drugs&#xD;
&#xD;
          -  likely to be not cooperative or comply with the trial requirements (as assessed by the&#xD;
             investigator), or unable to be reached in the case of an emergency&#xD;
&#xD;
          -  other antidiabetics&#xD;
&#xD;
          -  heart failure or heart failure in the patients history (NYHA I to IV)&#xD;
&#xD;
          -  history of macular oedema&#xD;
&#xD;
          -  treatment with thiazolidinediones within 3 months prior to screening&#xD;
&#xD;
          -  known or suspected history of alcohol and/or drug abuse&#xD;
&#xD;
          -  treatment with gemfibrozil within 3 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C Ludolph, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Center for Palliative Medicine, University of Munich</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>D-81366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>D-65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Goettingen</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>D-37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Muenster</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhrein-Westfalen</state>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>D-07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Humboldt University</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <reference>
    <citation>Schütz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schürmann B, Zimmer A, Heneka MT. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005 Aug 24;25(34):7805-12.</citation>
    <PMID>16120782</PMID>
  </reference>
  <reference>
    <citation>Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2005 Feb;191(2):331-6.</citation>
    <PMID>15649489</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>survival time</keyword>
  <keyword>ALS functioning Rating Scale</keyword>
  <keyword>quality of life</keyword>
  <keyword>non-invasive ventilation</keyword>
  <keyword>clinical tolerability</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

